Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

References

• ScoperSVBerdyGJLichtensteinSJPerception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisAdv Ther20072461221123218165204
   PubMed Web of Science ®Google Scholar
• CiprandiGBuscagliaSCerquetiPMCanonicaGWDrug treatment of allergic conjunctivitis. A review of the evidenceDrugs19924321541761372215
   PubMed Web of Science ®Google Scholar
• KatelarisCHBieloryLEvidence-based study design in ocular allergy trialsCurr Opin Allergy Clin Immunol20088548448818769206
   PubMed Web of Science ®Google Scholar
• BieloryLOcular allergy overviewImmunol Allergy Clin North Am2008281123 v18282543
   PubMed Web of Science ®Google Scholar
• SchatzMA survey of the burden of allergic rhinitis in the USAAllergy200762Suppl 8591617927673
   PubMed Web of Science ®Google Scholar
• BergerWAbelsonMBGomesPJEffects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapyAnn Allergy Asthma Immunol200595436137116279567
   PubMed Web of Science ®Google Scholar
• BieloryLGhafoorSHistamine receptors and the conjunctivaCurr Opin Allergy Clin Immunol20055543744016131920
   PubMed Web of Science ®Google Scholar
• SharifNAXuSXYanniJMOlopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitisJ Ocul Pharmacol Ther19961244014078951676
   PubMed Web of Science ®Google Scholar
• GalatowiczGAjayiYSternMECalderVLOcular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivoClin Exp Allergy200737111648165617877767
   PubMed Web of Science ®Google Scholar
• BieloryLAllergic and immunologic disorders of the eye. Part II: ocular allergyJ Allergy Clin Immunol200010661019103211112882
   PubMed Web of Science ®Google Scholar
• ChurchMKHolgateSTShuteJKMast cell derived mediatorsMiddletonEReedCEEllisETAllergy Principles and PracticeSt. Louis, MOMosby1988146167
   Google Scholar
• LeonardiANew drug treatments for ocular allergiesExpert Rev Ophthalmol20072397408
   Google Scholar
• BerdyGJSpanglerDLBenschGBerdySSBrusattiRCA comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge modelClin Ther20002278263310945509
   PubMed Web of Science ®Google Scholar
• LanierBQFinegoldID’ArienzoPGranetDEpsteinABLedgerwoodGLClinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge modelCurr Med Res Opin20042081227123315324525
   PubMed Web of Science ®Google Scholar
• SpanglerDLBenschGBerdyGJEvaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge modelClin Ther20012381272128011558863
   PubMed Web of Science ®Google Scholar
• BrockmanHLMomsenMMKnudtsonJRMillerSTGraffGYanniJMInteractions of olopatadine and selected antihistamines with model and natural membranesOcul Immunol Inflamm200311424726814704897
   PubMed Web of Science ®Google Scholar
• AbelsonMBSpanglerDLEpsteinABEfficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challengeCurr Eye Res200732121017102218085465
   PubMed Web of Science ®Google Scholar
• Pataday^™ [package insert]Fort Worth, TXAlcon Laboratories, Inc2006
   Google Scholar
• Elestat^® [package insert]Irvine, CAAllergan, Inc2003
   Google Scholar
• Patanol^® [package insert]Fort Worth, TXAlcon Laboratories, Inc2003
   Google Scholar
• Optivar^® [package insert]Somerset, NJMedPointe Pharmaceuticals2003
   Google Scholar
• Zaditor^® [package insert]Duluth, GANovartis Ophthalmics2001
   Google Scholar
• AbelsonMBGomesPJOlopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosingExpert Opin Drug Metab Toxicol20084445346118433347
   PubMed Web of Science ®Google Scholar
• MahFSRosenwasserLJTownsendWDGreinerJVBenschGEfficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challengeCurr Med Res Opin20072361445145217559743
   PubMed Web of Science ®Google Scholar
• ChippsBEGowerRKaufmanAA multi-center study evaluating patient perceptions of olopatadine 0.2% in patients with allergic conjunctivitis [abstract]2008Western Society of Asthma, Allergy, and Immunology annual meeting.
   Google Scholar
• CarrWWComparison of drop comfort of four marketed ocular anti-allergic medications [abstract]2007Eastern Allergy Conference annual meeting.
   Google Scholar
• AbelsonMBSchaeferKConjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapySurv Ophthalmol199338Suppl1151327901917
   PubMed Web of Science ®Google Scholar
• AbelsonMBWelchDLAn evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge modelActa Ophthalmol Scand Suppl2000230606311057354
   PubMedGoogle Scholar
• ScoperSVBerdyGJLichtensteinSJPerception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisAdv Ther20072461221123218165204
   PubMed Web of Science ®Google Scholar
• D’ArienzoPAGranetDBVariability of drop comfort and its importance as a criterion in the selection of topical therapy for ocular allergy [abstract]2001American Academy of Allergy, Asthma, and Immunology annual meeting, abstract #2002047.
   Google Scholar